<DOC>
	<DOCNO>NCT00015041</DOCNO>
	<brief_summary>The purpose study evaluate effect , pharmacokinetics dose proportionality buprenorphine administer non-dependent opiate user . 1 ) To evaluate whether plasma concentration buprenorphine increase proportionally buprenorphine dose . 2 ) To evaluate dose-response subjective physiological effect buprenorphine ; 3 ) To determine safety buprenorphine .</brief_summary>
	<brief_title>Buprenorphine Dose Escalation Trial Treatment Non-Dependent Opiate Users - 2</brief_title>
	<detailed_description>This open-label , single dose-escalation trial . A total 24 opiate experience , dependent subject receive four ascend dos buprenorphine , 4 , 8 , 16 , 24 mg , respectively , least 14 day washout interval treatment . The four treatment sublingual administration : 1. two 2-mg buprenorphine sublingual tablet , 2. one 8-mg buprenorphine sublingual tablet , 3. two 8-mg buprenorphine sublingual tablet ; 4. three 8-mg buprenorphine sublingual tablet . The dose proportionality plasma profile buprenorphine dose response buprenorphine sublingual tablet evaluate buprenorphine dose range 4 24 mg .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1 . Be male female race , 21 45 year age . 2 . Weigh within 15 % ideal body weight height accord current life insurance table . 3 . Be good physical mental health judge interview physical examination . 4 . Have significant oral cavity pathology include excessive caries , gingivitis , infectious inflammatory disease , recent pierce oral cavity . 5 . Be experienced illicit use opiates physically dependent opiate drug ( except nicotine caffeine ) time study . A history psychoactive drug use acceptable preference subject report less frequent control illicit drug use . 6 . For female subject , test nonpregnant use adequate birth control , lactate . 7 . Be capable provide write informed consent participate study . 8 . Be able comply protocol requirement likely complete four study treatment . 1 . Have diagnosis drug addiction ( nicotine , caffeine , opiate ) per DSMIV criterion . 2 . Have significant , active medical psychiatric illness ( drug dependence ) might inhibit ability complete study might complicate administration study medication . 3 . Have clinically significant abnormal laboratory measurement liver function test ( AST ALT level great 3 time upper limit normal ) , hematology ( CBC , differential , platelet count ) , serum chemistry ( SMA24 ) urinalysis screen . 4 . Test positive HIV blood screen . 5 . Have history significant hepatic , renal , endocrine , cardiac , nervous , psychiatric , gastrointestinal , pulmonary , hematologic metabolic disorder . 6 . Have know hypersensitivity buprenorphine derivative opiates opiatelike analgesic . 7 . Receive medication medical condition . 8 . Have condition history consider investigator ( ) place subject increase risk . 9 . Do actively meet inclusion criterion time screening .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 1998</verification_date>
	<keyword>opiate dependence</keyword>
</DOC>